Inhibikase Therapeutics, Inc. (IKT)
NASDAQ·Healthcare·Medical - Pharmaceuticals
$2.22
-3.90%
Mkt Cap $307.64M
Analyst Ratings
No recent rating data.
Price Target (3 analysts)
$4.00
Range $4.00 – $4.00
Implied Upside
+80.2%
Consensus $4.00 vs current $2.22